Drug Trial Radar · NCT04886804
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
554
Planned (sponsor's estimate)
Start
Jul 2, 2021
Primary completion
Feb 29, 2028
Study completion Aug 29, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.
Conditions
- Neoplasm Metastasis
- Non-Small Cell Lung Cancer
Interventions
zongertinibDrug
zongertinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Maximum Tolerated Dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21 days).
- Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation periodTime frame: At the end of Cycle 1 (each cycle is 21 days).
- Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
- Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
- Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
Locations
85 sites in 18 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Precision NextGen Oncology
Beverly Hills, California · Completed
City of Hope-Duarte-56419
Duarte, California · Recruiting
City of Hope - Seacliff
Huntington Beach, California · Completed
City of Hope-Irvine-69674
Irvine, California · Completed
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
University of California Irvine
Orange, California · Recruiting
University of California Davis
Sacramento, California · Recruiting
Georgetown University
Washington D.C., District of Columbia · Recruiting
Holy Cross Hospital-Fort Lauderdale-57892
Fort Lauderdale, Florida · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Recruiting
Hawaii Cancer Care - Honolulu
Honolulu, Hawaii · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Sarah Cannon Research Institute-Nashville-48456
Nashville, Tennessee · Recruiting
Mary Crowley Cancer Research Center
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Macquarie University
Macquarie Park, New South Wales, Australia · Completed
Ordensklinikum Linz GmbH
Linz, Austria · Completed
Brussels - HOSP Jules Bordet
Anderlecht/Brussels-Capital, Belgium · Active not recruiting
Beijing Cancer Hospital
Beijing, China · Completed
Jilin Province Cancer Hospital
Changchun, China · Completed
The First Hospital of Jilin University
Changchun, China · Active not recruiting
Fujian Cancer Hospital
Fuzhou, China · Active not recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Active not recruiting
The First Affiliated Hospital, Zhejiang University
Hangzhou, China · Active not recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Active not recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Active not recruiting
The Affiliated Cancer Hospital, Guangxi Medical University
Nanning, China · Completed
Shanghai Chest Hospital
Shanghai, China · Completed
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China · Active not recruiting
Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
Wuhan, China · Active not recruiting
First Affiliated Hospital of Xiamen University
Xiamen, China · Completed
Henan Cancer Hospital
Zhengzhou, China · Active not recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Active not recruiting
Hopital Louis Pradel
Bron, France · Active not recruiting
CTR Leon Berard
Lyon, France · Active not recruiting
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.